Monoclonal antibodies in the treatment of rheumatoid arthritis: toward a therapeutic revolution.

被引：4

作者：

Sany, Jacques ^{[1
]}

机构：

[1] CHU Montpellier, Serv Immunorheumatol, Hop Lapeyronie, F-34295 Montpellier 5, France

来源：

COMPTES RENDUS BIOLOGIES | 2006年 / 329卷 / 04期

关键词：

monoclonal antibodies; anti-TNF alpha monoclonal antibodies; anti-B lymphocytes monoclonal antibodies; anti-IL6 monoclonal antibodies; rheumatoid arthritis;

D O I：

10.1016/j.crvi.2005.12.008

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Monoclonal antibodies in the treatment of rheumatoid arthritis: toward a therapeutic revolution. The progress of immunopathology allowed the development of targeted drugs or biotherapies. Among them, monoclonal antibodies against T or B lymphocytes or against a cytokine are reported. Monoclonal anti-TNF antibodies are a major therapeutic advance because they can stop the clinical, biological and radiographic evolution of rheumatoid arthritis (RA). Monoclonal anti-CD20 lymphocytes give promising results; they are able to induce prolonged remissions. Monoclonal anti-IL6 receptors are currently being evaluated. They are efficacious in adult RA and in Still's disease. Because of the infectious risk linked to these drugs, the ratio benefit/risk must be carefully evaluated before the prescription of a biotherapy.

引用

页码：228 / 240

页数：13

共 59 条

[1] Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden [J].

Askling, J ;

Fored, CM ;

Brandt, L ;

Baecklund, E ;

Bertilsson, L ;

Cöster, L ;

Geborek, P ;

Jacobsson, LT ;

Lindblad, S ;

Lysholm, J ;

Rantapää-Dahlqvist, S ;

Saxne, T ;

Romanus, V ;

Klareskog, L ;

Feltelius, N .

ARTHRITIS AND RHEUMATISM, 2005, 52 (07) :1986-1992

[2]

Beenhouwer D, 2004, J RHEUMATOL, V31, P1888

[3]

BREEDVELD FC, 1998, RHEUM DIS CLIN N AM, P567

[4] C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis - Defining subtypes of nonresponse and subsequent response to etanercept [J].

Buch, MH ;

Seto, Y ;

Bingham, SJ ;

Bejarano, V ;

Bryer, D ;

White, J ;

Emery, P .

ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :42-48

[5] Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists [J].

Carmona, L ;

Gómez-Reino, JJ ;

Rodríguez-Valverde, V ;

Montero, D ;

Pascual-Gómez, E ;

Mola, EM ;

Carreño, L ;

Figueroa, T .

ARTHRITIS AND RHEUMATISM, 2005, 52 (06) :1766-1772

[6] Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints - Extended report [J].

Catrina, AI ;

Trollmo, C ;

af Klint, E ;

Engstrom, M ;

Lampa, J ;

Hermansson, Y ;

Klareskog, L ;

Ulfgren, AK .

ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :61-72

[7] Clinical experience with inhibition of interleukin-6 [J].

Choy, E .

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2004, 30 (02) :405-+

[8] Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial [J].

Choy, EHS ;

Isenberg, DA ;

Garrood, T ;

Farrow, S ;

Ioannou, Y ;

Bird, H ;

Cheung, N ;

Williams, B ;

Hazleman, B ;

Price, R ;

Yoshizaki, K ;

Nishimoto, N ;

Kishimoto, T ;

Panayi, GS .

ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3143-3150

[9]

Choy EHS, 1998, BRIT J RHEUMATOL, V37, P484

[10] Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients [J].

Choy, EHS ;

Connolly, DJA ;

Rapson, N ;

Jeal, S ;

Brown, JCC ;

Kingsley, GH ;

Panayi, GS ;

Johnston, JM .

RHEUMATOLOGY, 2000, 39 (10) :1139-1146

← 1 2 3 4 5 6 →